Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients: A Literature Review

Journal of the International Association of Providers of AIDS Care

Volumn 14, Issue 5, 2015, Pages 402-407

  Badaró, Roberto ^a   Gonçalves, Larissa O ^a   Gois, Luana L ^b,c   Maia, Zuinara Pereira Gusmão ^a   Benson, Constance ^d   Grassi, Maria Fernanda Rios ^b,c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

co infection HIV Leishmania; HIV AIDS; immune reconstitution inflammatory syndrome; IRIS; leishmaniasis

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEISHMANIASIS; PRIORITY JOURNAL; REVIEW; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; TEGUMENTARY LEISHMANIASIS; UVEITIS; VISCERAL LEISHMANIASIS; ADULT; AIDS RELATED COMPLEX; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PARASITOLOGY; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEISHMANIASIS; MALE; MIDDLE AGED;

EID: 84941959955     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957414555225     Document Type: Review

References (46)

1. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002; 81 (3): 213-227.
2. Shelburne SA 3rd, Hamill RJ,. The immune reconstitution inflammatory syndrome. AIDS Rev. 2003; 5 (2): 67-79.
3. Barber DL, Andrade BB, Sereti I, Sher A,. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol. 2012; 10 (2): 150-156.
4. Murdoch DM, Venter WD, Van Rie A, Feldman C,. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007; 4: 9.
5. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M,. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10 (4): 251-261.
6. Lawn SD, Wilkinson RJ,. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol. 2006; 28 (11): 625-633.
7. Gelanew T, Amogne W, Abebe T, Kuhls K, Hailu A, Schonian G,. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy. Br J Dermatol. 2010; 163 (4): 870-874.
8. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN,. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008; 46 (11): 1702-1709.
9. Auyeung P, French MA, Hollingsworth PN,. Immune restoration disease associated with Leishmania donovani infection following antiretroviral therapy for HIV infection. J Microbiol Immunol Infect. 2010; 43 (1): 74-76.
10. Sinha S, Fernandez G, Kapila R, Lambert WC, Schwartz RA,. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol. 2008; 47 (12): 1263-1270.
11. Kerob D, Bouaziz JD, Sarfati C, et al. First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis. Clin Infect Dis. 2006; 43 (5): 664-666.
12. Patel KK, Patel AK, Sarda P, Shah BA, Ranjan R,. Immune reconstitution visceral leishmaniasis presented as hemophagocytic syndrome in a patient with AIDS from a nonendemic area: a case report. J Int Assoc Physicians AIDS Care (Chic). 2009; 8 (4): 217-220.
13. Antinori S, Longhi E, Bestetti G, et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol. 2007; 157 (5): 1032-1036.
14. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H,. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis. 2005; 192 (10): 1819-1822.
15. Gilad J, Borer A, Hallel-Halevy D, Riesenberg K, Alkan M, Schlaeffer F,. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Isr Med Assoc J. 2001; 3 (6): 451-452.
16. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg. 2009; 81 (4): 559-564.
17. Ridolfo AL, Gervasoni C, Antinori S, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect. 2000; 40 (2): 199-202.
18. Blanche P, Gombert B, Rivoal O, Abad S, Salmon D, Brezin A,. Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis. 2002; 34 (9): 1279-1280.
19. Bittencourt A, Silva N, Straatmann A, Nunes VL, Follador I, Badaro R,. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis. 2003; 7 (3): 229-233.
20. Berry A, Abraham B, Dereure J, Pinzani V, Bastien P, Reynes J,. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis. 2004; 36 (3): 225-227.
21. Meenken C, van Agtmael MA, Ten Kate RW, van den Horn GJ,. Fulminant ocular leishmaniasis in an HIV-1-positive patient. AIDS. 2004; 18 (10): 1485-1486.
22. Alsina-Gibert M, Lopez-Lerma I, Martinez-Chamorro E, Herrero-Mateu C,. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient. Arch Dermatol. 2006; 142 (6): 787-789.
23. Tadesse A, Hurissa Z,. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART). Ethiop Med J. 2009; 47 (1): 77-79.
24. Stark D, Pett S, Marriott D, Harkness J,. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol. 2006; 44 (3): 1178-1180.
25. Guffanti M, Gaiera G, Bossolasco S, et al. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. Am J Trop Med Hyg. 2008; 79 (5): 715-718.
26. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE,. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect. 2006; 53 (1): e25-e27.
27. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis. 1998; 177 (5): 1339-1344.
28. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2001; 32 (4): 633-635.
29. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G,. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008; 68 (2): 191-208.
30. Cavalcanti AT, Medeiros Z, Lopes F, et al. Diagnosing visceral leishmaniasis and HIV/AIDS co-infection: a case series study in Pernambuco, Brazil. Rev Inst Med Trop Sao Paulo. 2012; 54 (1): 43-47.
31. Ngouateu OB, Kollo P, Ravel C, et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg. 2012; 106 (3): 137-142.
32. Goto H, Lindoso JA,. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010; 8 (4): 419-433.
33. Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol. 2009; 160 (2): 311-318.
34. Eickelmann M, Steinhoff M, Metze D, Tomimori-Yamashita J, Sunderkotter C,. Erythema leprosum - after treatment of Lepromatous Leprosy. J Dtsch Dermatol Ges. 2010; 8 (6): 450-453.
35. Vieira JL, Valente Mdo S,. Thalidomide levels in patients with erythema nodosum leprosum. Ther Drug Monit. 2009; 31 (5): 602-603.
36. Villahermosa LG, Fajardo TT Jr, Abalos RM, et al. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg. 2005; 72 (5): 518-526.
37. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997; 277 (5322): 112-116.
38. Carcelain G, Debre P, Autran B,. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol. 2001; 13 (4): 483-488.
39. Stone SF, Price P, Keane NM, Murray RJ, French MA,. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med. 2002; 3 (1): 21-27.
40. Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010; 116 (19): 3818-3827.
41. Morlese JF, Orkin CM, Abbas R, et al. Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS. 2003; 17 (9): 1411-1413.
42. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS. 2006; 20 (2): F1-F7.
43. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 2008; 9 (5): 307-316.
44. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med. 2008; 178 (10): 1083-1089.
45. Tieu HV, Ananworanich J, Avihingsanon A, et al. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retroviruses. 2009; 25 (11): 1083-1089.
46. Lim A, D'Orsogna L, Price P, French MA,. Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res Ther. 2008; 5: 9.